trifluridine / tipiracil
Lonsurf is a medicine used to treat adults with colorectal cancer (cancer of the large bowel) and gastric (stomach) cancer that is metastatic (has spread to other parts of the body). It is used in patients who have already been treated with, or who cannot be given, other treatments for their cancer. It can be used in combination with bevacizumab (another cancer medicine) to treat colorectal cancer.
Lonsurf contains the active substances trifluridine and tipiracil.
Lonsurf : EPAR - Medicine overview (PDF/111.2 KB) (updated)
First published: 12/05/2016
Last updated: 11/09/2023
Lonsurf : EPAR - Risk-management-plan summary (PDF/112.34 KB) (updated)
First published: 08/10/2019
Last updated: 11/09/2023
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Les Laboratoires Servier
|Date of issue of marketing authorisation valid throughout the European Union||
50 rue Carnot
92284 Suresnes cedex
26/07/2023 Lonsurf - EMEA/H/C/003897 - II/0026
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Lonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agents
Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 201626/02/2016